Tesamorelin 10mg

Tesamorelin Peptide

Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH). It consists of the first 44 amino acids of human GHRH with a 3-hexenoic acid group attached to the N-terminal tyrosine residue. This structural modification enhances its stability and resistance to enzymatic degradation by dipeptidyl peptidase-4 (DPP-4), resulting in a significantly longer half-life compared to the natural hormone.

Unlike direct growth hormone (GH) administration, Tesamorelin acts as a secretagogue, stimulating the pituitary gland to synthesize and release endogenous growth hormone in a pulsatile manner. By preserving the natural negative feedback loop involving somatostatin, Tesamorelin increases GH levels without the common risks of overdose or total suppression of the natural pituitary-axis associated with exogenous GH.

---

Overview

Tesamorelin is primarily recognized in the scientific community for its potent lipolytic properties, specifically its ability to target visceral adipose tissue (VAT). While many metabolic interventions affect subcutaneous fat, Tesamorelin specifically modulates the GHRH-GH-IGF-1 axis to influence the breakdown of deep abdominal fat deposits.

Research suggests that the increase in growth hormone levels induced by Tesamorelin promotes protein synthesis and stimulates the production of Insulin-like Growth Factor 1 (IGF-1) in the liver. This cascade is believed to be the primary driver behind its ability to reduce ectopic fat while maintaining muscle mass. Researchers are currently investigating its broader applications in liver health, cognitive function, and metabolic syndrome.

---

Chemical Makeup

• Molecular Formula: C221H366N72O67
• Molecular Weight: 5135.86 g/mol
• Other Known Titles: Egrifta, TH9507

---

Research Studies and Clinical Trials

Tesamorelin and Visceral Fat Reduction

In pivotal Phase 3 clinical trials, researchers evaluated the impact of Tesamorelin on abdominal fat accumulation. Over a 26-week period, subjects receiving the peptide showed a mean reduction in visceral adipose tissue (VAT) of approximately 18%, measured by CT scan. Notably, these studies observed that the reduction was specific to visceral fat, with minimal changes to subcutaneous fat, highlighting its unique role in targeting metabolically active, “dangerous” abdominal fat.

Impact on Metabolic Profiles and Lipid Metabolism

Research has indicated that the reduction in visceral fat following Tesamorelin administration correlates with improvements in lipid profiles.Studies observed significant decreases in triglycerides and non-HDL cholesterol levels. Unlike some GH-related therapies that can impair glucose tolerance, Tesamorelin has generally shown a neutral effect on glucose metabolism in large-scale trials, though researchers continue to monitor HbA1c levels in subjects with pre-existing insulin resistance.

Tesamorelin and Hepatic Health (NAFLD/MASLD)

Recent investigations have explored Tesamorelin’s potential in treating non-alcoholic fatty liver disease (NAFLD). Because growth hormone plays a vital role in hepatic lipid oxidation, researchers used MR spectroscopy to measure liver fat fractions. Results suggested that Tesamorelin significantly reduced hepatic fat content and prevented the progression of liver fibrosis in certain cohorts, positing the GHRH pathway as a therapeutic target for metabolic liver disorders.

Potential Neuroprotective and Cognitive Effects

Preliminary studies have looked beyond metabolism to the effects of GHRH analogues on the central nervous system. Some clinical data suggests that by increasing systemic IGF-1 levels, Tesamorelin may provide neuroprotective benefits. Researchers have noted improvements in executive function and memory in older adults with mild cognitive impairment, leading to ongoing interest in its role in aging-related cognitive decline.